Psychemedics Corporation (PMD)
- Previous Close
2.6800 - Open
2.6125 - Bid --
- Ask --
- Day's Range
2.5400 - 2.6400 - 52 Week Range
2.0600 - 5.5900 - Volume
3,141 - Avg. Volume
8,998 - Market Cap (intraday)
14.746M - Beta (5Y Monthly) 0.70
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7200 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield 0.28 (11.02%)
- Ex-Dividend Date May 24, 2023
- 1y Target Est
--
Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company's testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The company was incorporated in 1986 and is headquartered in Dallas, Texas.
www.psychemedics.com116
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: PMD
Performance Overview: PMD
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PMD
Valuation Measures
Market Cap
14.75M
Enterprise Value
15.08M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.66
Price/Book (mrq)
2.21
Enterprise Value/Revenue
0.68
Enterprise Value/EBITDA
-60.08
Financial Highlights
Profitability and Income Statement
Profit Margin
-18.80%
Return on Assets (ttm)
-11.76%
Return on Equity (ttm)
-47.63%
Revenue (ttm)
22.1M
Net Income Avi to Common (ttm)
-4.15M
Diluted EPS (ttm)
-0.7200
Balance Sheet and Cash Flow
Total Cash (mrq)
1.96M
Total Debt/Equity (mrq)
34.44%
Levered Free Cash Flow (ttm)
926.75k